A paper authored by members of an American Society of Clinical Oncology Task Force illuminates the importance of enabling patients to receive trial-related testing and care near their homes, rather than requiring patients to travel long distances to reach major research institutions.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
